Doctors More Cautious Now When Prescribing Opioids to Kids

There's been a steady decline in opioid prescriptions for children and teens in the United States since 2012, a new study reveals.
"Understanding patterns of opioid use in children and adolescents is important because use in early life has been associated with a higher likelihood of opioid misuse in the future," said the study's first author, Joshua Gagne. He's with the division of pharmacoepidemiology and pharmacoeconomics at Brigham and Women's Hospital in Boston.
Prior studies found that the rate of hospitalizations due to opioid poisonings nearly doubled among American children and adolescents between 1997 and 2012.
"We sought to examine more recent opioid prescribing trends in younger populations as this age group has been consistently understudied," Gagne said in a hospital news release.
The researchers examined 2004-2017 data from a commercial insurance provider. They found that in 2004, an average of 3 in every 1,000 children under age 18 had received an outpatient opioid prescription in a given month.
Between 2009 and 2012, that rose to 4 in 1,000. By 2017, however, the number had dropped to 2 per 1,000 children, according to the study.
"These results show that prescription opioids dispensed to children and adolescents have been decreasing since 2012," the study authors wrote.
"Despite the downward trends for opioid prescriptions, the frequency of opioid use remains high given the risks associated with these medications in younger populations," the researchers concluded.
Looking for chemical products? Let suppliers reach out to you!
2026-07-17
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Sun Pharma’s Ilumya Hits Primary Endpoint in Two Phase 3 Trials for Psoriatic Arthritis $681 Million Drug Shows Significant Improvement at Week 24
-
Sanofi’s $2.2 Billion Dynavax Acquisition: Why Big Pharma Is Rebuilding the Global Vaccine Order
-
Bristol Myers’ Reblozyl Misses Main Goal in Cancer Anemia Study $1.77 Billion Drug Faces Setback but Shows Some Benefits
-
India’s Pharma Cost Problem Gets Worse
-
FDA Fast-Tracks U.S. Drug Manufacturing
-
Novartis Boosts 2025 Earnings Forecast as US Tariff Risks Loom $23 Billion Investment and $10 Billion Buyback Unveiled
-
FDA Warning Letters Put GMP Back in Focus
-
India Targets Fake Drug Packaging
-
Zydus Lifesciences Blocked by Delhi High Court in Cancer Biosimilar Case $9.3 Billion Opdyta Patent Dispute Intensifies
-
Minoxidil Safety Under Global Review as Infant Exposure Risks Surface
Recommend Reading
-
Substandard Drug Findings Expose Deep Structural Gaps in Medicine Quality Control
-
Obesity Drugs Become Pharma’s Most Powerful Growth Engine
-
Indian Immunologicals Pushes Back on “Fake Vaccine” Claims Amid Global Supply Chain Scrutiny
-
Glenmark Targets 10–15 Percent CAGR in India by Shifting to High-Margin Drugs AbbVie Deal and New Launches Boost Outlook
-
Wall Street Predicts New Obesity Pills Will Be Priced Near $1000 Like Wegovy and Zepbound Supply and Competition Pressures Mount
-
China's urea market shows a strong upward trend (10.20-10.24)
-
Supply-demand contradiction difficult to alleviate, polyethylene remains weak
-
FDA Moves to Revoke 52 Outdated Food Standards Major Changes for Dairy, Canned Goods and Baked Products
-
This Week, China's Titanium Dioxide Market Remains Stable (10.20-10.24)
-
“Zero Tariff Is Not a Get-Out-of-Jail-Free Card”: Hainan’s Full Customs Closure—Boon or Trap for the Chemical Industry?